|Rating 4.6 / 5|
Diabeton MV (Diabeton MR): 2 reviews of doctors, 3 reviews of patients, instructions for use, analogues, infographics, 1 form of release.
Doctors reviews about diabetes mellitus MV
|Rating 4.2 / 5|
With decompensation of diabetes, the drug compensates for glycemia perfectly. Modified release prevents hypoglycemia, therefore, the drug is suitable for elderly patients, as well as patients with diseases of the cardiovascular system.
Rarely, but can cause hypoglycemia.
I use the drug very widely in my practice. The price is reasonable, the efficiency is excellent.
|Rating 5.0 / 5|
The drug "Diabeton MV" is used in various dosages of 30 or 60 mg. These are modified release tablets. The drug has a very effective and even profile of action. There are no side effects, the effect of the drug begins after a fairly quick time. Well established for the treatment of diabetes.
Patient Reviews for Diabeton MV
My husband has high sugar. For several years, they were looking for a drug that would lower his sugar and, most importantly, keep his level normal. During the next consultation with the attending physician, we were advised the drug “Diabeton MV”. After a month's course of taking the drug, sugar returned to normal. Now my husband has 8.2 mm. This, of course, is a slightly elevated level. But it is better than the 13-15 mm that were before.
Prescribed "Diabeton" dosage of 60 mg per day, not very well reduced. In the morning there was sugar 10-13. Then the doctor increased the dosage to 90 mg (1.5 tab). Now in the morning, when I measure sugar, it was even 6. I must say that a lot more depends on whether I strictly adhere to the diet. Just the same 6 was when there were no eating disorders. Of course, plus a little physical activity.
I have been taking it for a year, good effect, the effect is noticeable and speedy. Side effects do not occur. Great remedy.
Oral hypoglycemic agent, a sulfonylurea derivative of the second generation. Stimulates the secretion of insulin by β-cells of the pancreas. Increases the sensitivity of peripheral tissues to insulin. Apparently, it stimulates the activity of intracellular enzymes (in particular, muscle glycogen synthetase). Reduces the time interval from the moment of eating to the start of insulin secretion. Restores the early peak of insulin secretion, reduces the postprandial peak of hyperglycemia.
Glyclazide reduces platelet adhesion and aggregation, slows down the development of a parietal thrombus, and increases vascular fibrinolytic activity. Normalizes vascular permeability. It has anti-atherogenic properties: it lowers the concentration of total cholesterol (Ch) and LDL-C in the blood, increases the concentration of HDL-C and also reduces the number of free radicals. Prevents the development of microthrombosis and atherosclerosis. Improves microcirculation. Reduces vascular sensitivity to adrenaline.
With diabetic nephropathy with prolonged use of gliclazide, a significant decrease in proteinuria is noted.
After oral administration, it is rapidly absorbed from the digestive tract. Cmax in blood is reached approximately 4 hours after taking a single dose of 80 mg.
Plasma protein binding is 94.2%. Vd - about 25 l (0.35 l / kg body weight).
It is metabolized in the liver with the formation of 8 metabolites. The main metabolite does not have a hypoglycemic effect, but has an effect on microcirculation.
T1/2 - 12 hours. It is excreted mainly by the kidneys in the form of metabolites, less than 1% is excreted in the urine unchanged.
The modified-release tablets are white, oblong, engraved on both sides: on one is the logo of the company, on the other - "DIA30".
Excipients: calcium hydrogen phosphate dihydrate, maltodextrin, hypromellose, magnesium stearate, anhydrous colloidal silicon dioxide.
30 pcs - blisters (1) - packs of cardboard.
30 pcs - blisters (2) - packs of cardboard.
The hypoglycemic effect of gliclazide is potentiated with simultaneous use with pyrazolone derivatives, salicylates, phenylbutazone, antibacterial sulfonamide drugs, theophylline, caffeine, MAO inhibitors.
The simultaneous use with non-selective beta-blockers increases the likelihood of developing hypoglycemia, and can also mask tachycardia and hand tremor, characteristic of hypoglycemia, while sweating may increase.
With the simultaneous use of gliclazide and acarbose, an additive hypoglycemic effect is observed.
Cimetidine increases the concentration of gliclazide in plasma, which can cause severe hypoglycemia (CNS depression, impaired consciousness).
With simultaneous use with GCS (including dosage forms for external use), diuretics, barbiturates, estrogens, progestins, combined estrogen-progestogen drugs, diphenin, rifampicin, the hypoglycemic effect of glyclazide is reduced.
From the digestive system: rarely - anorexia, nausea, vomiting, diarrhea, epigastric pain.
From the hemopoietic system: in some cases - thrombocytopenia, agranulocytosis or leukopenia, anemia (usually reversible).
From the endocrine system: with an overdose - hypoglycemia.
Allergic reactions: skin rash, itching.
Type 2 diabetes mellitus with insufficient effectiveness of diet therapy, physical activity and weight loss.
Prevention of complications of type 2 diabetes mellitus: reducing the risk of microvascular (nephropathy, retinopathy) and macrovascular complications (myocardial infarction, stroke).
Gliclazide is used to treat non-insulin-dependent diabetes mellitus in combination with a low-calorie, low-carb diet.
During treatment, you should regularly monitor the level of glucose in the blood on an empty stomach and after eating, daily fluctuations in glucose levels.
In the case of surgical interventions or decompensation of diabetes mellitus, it is necessary to take into account the possibility of using insulin preparations.
With the development of hypoglycemia, if the patient is conscious, glucose (or a solution of sugar) is prescribed inside. In case of loss of consciousness, intravenous glucose or glucagon sc, intramuscularly or intravenously are administered. After regaining consciousness, it is necessary to give the patient food rich in carbohydrates in order to avoid the re-development of hypoglycemia.
With the simultaneous use of gliclazide with verapamil, regular monitoring of blood glucose levels is required, with acarbose, careful monitoring and correction of the dosage regimen of hypoglycemic agents is required.
The simultaneous use of gliclazide and cimetidine is not recommended.